Wall Street's Largest IPO of 2025 Is a $50 Billion Test of Private Equity's Exit Strategy

Wall Street's Largest IPO of 2025 Is a $50 Billion Test of Private Equity's Exit Strategy

Medline Industries filed final terms today for what will be the largest U.S. initial public offering of 2025: 179 million shares priced between $26 and $30, targeting up to $5.37 billion in gross proceeds. The medical supply giant—owned by Blackstone, Carlyle, and Hellman & Friedman since a $34 billion leveraged buyout in 2021—will list on Nasdaq under ticker MDLN, with Goldman Sachs, Morgan Stanley, BofA Securities, and J.P. Morgan leading the deal. Pricing is expected before year-end, with roadshow meetings beginning this week.

The numbers tell the story of scale: Medline generated $25.5 billion in net sales over the twelve months ending June 2025, with first-half revenue of $13.5 billion up 9.7% year-over-year and net income of $655 million. The company manufactures and distributes everything from surgical gloves to hospital gowns, commanding an estimated 30% share of the U.S. medical supply market. At the implied $50 billion valuation, this represents a 47% gain on the sponsors' 2021 entry price—not spectacular by private equity standards, but meaningful liquidity in a market that has starved PE firms of exits for three years.

The Structural Forces Behind the Rush

This is not an isolated event. Private equity-backed IPOs surged 40% year-over-year in Q3 2025, the strongest quarter since 2022, with healthcare claiming nine of 23 PE-backed U.S. listings in the first half. The medical supply subsector alone logged 12 private equity exits totaling $3.09 billion through October—more than double 2024's pace. Medline's timing exploits a narrow window: Federal Reserve rate cuts (down to 3.75-4.0% from 5.5% peaks), S&P 500 gains of 17% year-to-date, and post-election regulatory clarity have reignited investor risk appetite after a two-year drought that saw IPO volumes crater 80% from 2021 highs.

The urgency is structural. Private equity firms hold $2.7 trillion in global dry powder but managed exits representing just 8% of assets under management in 2024. Firms like Blackstone sat on over $1 trillion in unrealized gains while high interest rates made debt service consume 40% of portfolio company EBITDA. Now, with borrowing costs down 150 basis points, sponsors are racing to monetize holdings before macro conditions shift again. Medline's $16.8 billion debt load—nearly 5x its $3.4 billion adjusted EBITDA—makes deleveraging from IPO proceeds not optional but existential.

The Investment Calculus: Quality at a Private Equity Price

Here is where professional money managers face the hard decision. Medline is undeniably a high-quality asset: dense distribution networks, 30,000 employees, recession-resistant end markets tied to aging demographics and procedure volumes, and a private-label manufacturing business contributing 49% of sales but over 80% of segment EBITDA. The moat is operational, not technological—logistics sophistication and SKU breadth that make it costly for hospital systems to switch vendors.

But the valuation demands scrutiny. At $50 billion equity value and $16.8 billion net debt, enterprise value reaches $66.8 billion—implying 19.6x EV/EBITDA on 2024's $3.4 billion. Compare that to publicly traded peers: McKesson trades at 16x, Cardinal Health at 14-15x, and healthcare distribution deals in 2025 cleared at 9-12x on average. Medline's free cash flow of approximately $1.2-1.4 billion (normalized for working capital swings) yields just 2% on enterprise value. You are paying a premium for quality, but leaving minimal margin for execution missteps or macro shocks.

The structure compounds concerns. Medline employs an Up-C partnership vehicle where pre-IPO owners retain voting control and a Tax Receivable Agreement obligates the public company to pay sponsors a percentage of future tax savings—"substantial" cash leakage the S-1 explicitly warns about. With only 10% free float at launch, this is a controlled PE exit, not a founder-led growth story.

For fundamental investors, the calculus is clear: great business, mediocre entry point. Medline becomes compelling if pricing flexes down or post-IPO weakness creates an opportunity to buy quality below 17x EBITDA while the company demonstrably pays down debt. But at full valuation, this is private equity engineering meeting defensive investor demand—a test of whether 2025's IPO revival has legs, or whether late-cycle pricing will chill the $200 billion pipeline of PE exits queued for 2026.

NOT INVESTMENT ADVICE